Confirmed
One controlled phase 3 trial met its main goal, and siponimod is approved for this use.
S1P receptor modulation (lymphocyte trafficking): slow disability worsening in secondary progressive MS
secondary progressive MS · S1P receptor modulation (lymphocyte trafficking)
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 2
- Running now
- 1
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 1651
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)decides the statusMet main goal
Phase 3 · 2012 · Placebo-controlled · MSFT-NCT01665144
Other linked trials: 1
These linked trials do not set the status.
- SIPO20Ongoing
Phase 4 · 2022 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28First listed as Confirmed
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error